Speed and efficiency – from discovery to approval to market and beyond – are fundamental to the success of today’s biopharmaceutical enterprise. Making decisions faster and introducing efficiencies at every stage of the drug development cycle is now accepted dogma, but the search continues for something more transformative to boost pipeline productivity and growth.
One answer may lie in the arrival of replicable, synthetic versions of DNA, the design atelier behind the most cost-effective, perfectly engineered structure of all: the human body. By replicating the processing and storage power latent in individual strands of DNA, scalable volumes of genes, proteins and other genetic material can be engineered by scientists in the lab to help drug developers design and test novel, personalized medicines more cheaply and at a faster rate than conventional search and discover methods